Introduction {#Sec1}
============

For the past two decades, the prevalence of asthma has substantially increased in both the developed and developing countries (Osborne et al. [@CR45]). The International Study of Asthma and Allergies in Childhood (ISAAC) study demonstrated that across 37 countries including the US and the UK, the average prevalence of asthma in 2006 amongst children aged 6--7 years was 12.6% (Asher et al. [@CR4]). The Global Burden of Disease attributed to asthma is predicted to be about 11 million years of life lost (YLLs) and 25 million disability-adjusted life years (DALYs) per year (Osborne et al. [@CR45]).

Asthma is a common chronic disease in children and adults characterised by airway inflammation and increased mucus production---leading to airway obstruction (Khalili et al. [@CR32]). It is estimated by the US Centers for Disease Control and Prevention (CDC) that 6.8% of US working adults have current asthma---defined as having had at least one asthma attack or visit the emergency department (ED) for asthma in the past 12 months (Mazurek and Syamlal [@CR38]). The disease is a potential threat to children's growth and development including their educational achievement (Nurmagambetov et al. [@CR44]). In 2017, the prevalence of asthma was reported in approximately 6.2 million children in the US---about 8.4% of children under the age of 18 (CDC [@CR17]). The US annual economic costs associated with asthma have been estimated at \$81 billion for 2013, including treatment costs and mortality costs valued using the value of statistical life and lost work and school days (Nurmagambetov et al. [@CR44]). The root causes of asthma have not been fully elucidated, but genetic predisposition, and environmental factors including allergens and chemicals (such as phthalates) as well as gene-environment interactions, have been suggested as important risk factors for asthma pathogenesis and exacerbations (Wang et al. [@CR53]; Sordillo et al. [@CR47]; Surdu et al. [@CR48]).

Phthalates are synthetic chemicals produced by reacting phthalic anhydride with different chain lengths of alcohol(s) which may vary from single chain alcohol (such as methanol) to multiple chain alcohol (such as tridecyl alcohol) (Benjamin et al. [@CR7]). They are mainly classified into two types---high (HMW) and low molecular weight (LMW) phthalates---and their uses may in part depend on their molecular weight (Table [1](#Tab1){ref-type="table"}) (Braun et al. [@CR12]; Benjamin et al. [@CR7]). Phthalates are omnipresent and are not covalently bound to the consumer products; they easily leach out and make their way to the environment (Tsai et al. [@CR50]). Humans are exposed to these chemicals through several routes of exposure including water, breathing air, dermal contact, during medical treatment and, importantly, via food (Benjamin et al. [@CR7]).Table 1Commonly used phthalates, their molecular weights and primary metabolites. Adapted from Braun et al. ([@CR12]) and Benjamin et al. ([@CR7])Commonly used phthalates (parent compound)AbbreviationMetabolites measured in epidemiological studiesMolecular weight (MW)Uses/applicationsHigh molecular weight (HMW) phthalates  Di- (2-ethylhexyl) phthalateDEHPa) Mono-(2-ethylhexyl) phthalate (MEHP)b) Mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP)c) Mono-(2-ethyl-5-hydroxylhexyl) phthalate (MEHHP)d) Mono-(2-ethyl-5-carboxylpentyl) phthalate (MECPP)390.56Plasticiser for PVC including medical tubing (blood bags, syringes and dialysis equipment), construction and automotive, some food packaging, flooring and floor tiles, toys, solvents in lip sticks, plastic films, gloves, shower curtains, wall covering, ethyl cellulose resin (such as electric wire, imitation leather, mould plastic products and rain wears.  Di-isononyl phthalateDiNPa) Mono-(carboxyloctyl) phthalate (MCOP)b) Mono-isononyl phthalate (MiNP)418.61PVC sheeting, building and construction materials, foot wears, sealing, several categories of toys (plastic books, ball, doll and cartoon characters), paints, automotive parts adhesives, printing ink for t-shirts, soap packaging, resins, and electrical wires and cables, etc.  Di-isodecyl phthalateDiDPMono-(carboxylnonyl) phthalate (MCNP)446.66Plasticiser in PVC, pharmaceutical pills, food wrappers, plastic paste for coating, textile inks, PVCFlooring materials, hollow plastic products such as toys, exercise balls, and hoppers, and adhesives.  Di-n-octyl phthalateDnOPMono (3-carboxylpropyl) phthalate (MCPP)390.56Plasticiser in PVC, paints, lacquers, adhesives, flooring tiles.  Benzylbutyl phthalateBBzPa) Mono-benzyl phthalate (MBzP)b) Mono (3-carboxylpropyl) phthalate (MCPP)278.34Cellulose, varnishes, toys, childcare articles, school supplies, children clothes, acetate plastics, personal care products (including nail polish and cosmetics) and fragrance ingredients.Low molecular weight (LMW) phthalates  Di-butyl phthalateDBPa) Mono-n-butyl phthalate (MnBP)b) Mono (3-carboxylpropyl) phthalate (MCPP)278.34Cellulose acetate plastics, personal care products, varnishes, pharmaceutical coatings and fragrance ingredients.  D-imethyl phthalateDMPMono-methyl phthalate (MMP)194.18Fragrance ingredients for cosmetics, domestic and personal care product, adhesives, children's toys, lacquers, paints, plastics and rubbers.  Di-ethyl phthalateDEPMono-ethyl phthalate (MEP)222.24Personal care items (fragrances), pharmaceutical coatings and packaging, dyes, nail polish, perfumes as a solvent, ingredient in aspirin coating, surface lubricants in food, automotive parts, adhesives and plasticisers.

Although phthalates are easily bio-transformed and excreted (leading to lesser bioaccumulation), regular exposure in humans may exacerbate the risk of developing asthma or prolong its prevalence by binding with and activating peroxisome proliferator-activated receptors (PPARs) which mediate anti-inflammatory effects in the lungs and immune systems (Bølling et al. [@CR10]); increasing the proliferation of the bronchial muscle cells which may lead to airways remodelling (Kuo et al. [@CR35]); promoting the production of pro-inflammatory cytokines IL-6 and IL-8 in the airway epithelial cells (Jepsen et al. [@CR30]); and/or; acting as an adjuvants by enhancing macrophage production of inflammatory cytokines and chemokines (Nishioka et al. [@CR43]).

Several epidemiological studies have demonstrated that regular exposure to phthalates is associated with an increased risk of non-communicable chronic diseases including cardiovascular diseases and diabetes (Dong et al. [@CR20]; Bai et al. [@CR5]). Limited information is known about the association between phthalates exposure and the prevalence of asthma (Benjamin et al. [@CR7]), with available evidence producing inconsistent results. A meta-analysis demonstrated that post-natal exposure to di-(2-ethylhexyl) phthalate (DEHP) and butylbenzyl phthalate (BBzP) from dust and prenatal urinary mono-benzyl phthalate (MBzP) were significantly associated with childhood asthma (Li et al. [@CR37]).

In contrast, a recent study has shown that both LMW and HMW phthalates (including DEHP) were not associated with the report of doctor-diagnosed asthma (Vernet et al. [@CR52]). Previous research found that the urinary concentration of MBzP metabolite was associated with self-reported asthma in adults but not in children (Hoppin et al. [@CR24]). These inconsistencies need to be addressed with more research into the potential association between phthalates and asthma in children and adults using a large cross-sectional secondary data and better outcome measures (for example spirometry and questionnaire data).

In addition, the development and/or exacerbation of asthma may be sex-specific. Whilst the prevalence of asthma, in general, is greater in females than in males (CDC [@CR16]), investigation at a specific time point revealed otherwise. Before age 13--14 years, the incidence and prevalence of asthma with increased wheeze, use of asthma medications and serum IgE level are greater among boys than among girls (Wijga et al. [@CR56]; Almqvist et al. [@CR3]; Bjornson and Mitchell [@CR9]). By contrast, studies through puberty and beyond have found a greater increase in the incidence and prevalence of asthma among adolescent and young adult females (CDC [@CR16]; De Marco et al. [@CR19]). Importantly, a prospective cohort study demonstrated that the relationship between phthalates and asthma may be modified by sex (Buckley et al. [@CR13]), with 5-year-old boys at increased odds of asthma occurrence following exposures to mono-(2-ethylhexyl) phthalate (MEHP) and mono-ethyl phthalate (MEP) (Ku et al. [@CR34]).

In the current study, we polled the National Health and Nutrition Examination Survey (NHANES) 2007--2012 data to examine the direction and strength of the association between urinary phthalate metabolites and current asthma in children and adults. As a secondary aim, we stratified the data based on the participant sex, to investigate whether the effect measure was modified by sex in both children and adults.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

NHANES is a nationally representative, multi-stage, population-based, cross-sectional study carried out by the US National Centre for Health Statistics (NCHS). It was designed to assess the health and nutritional status of civilian, non-institutionalised children and adults in the US. Respondents for our study were children aged between 6 and 17 years, and adults aged 18 and 79 years, who were randomly selected by the NHANES for urinary phthalates measurement; and who had complete information on self-reported questionnaires, spirometry and confounding variables. Participants aged 80 years and over were excluded in order to reduce biases resulting from the non-representation of the older adults who are institutionalised after 80 years.

Data were pooled from three independent cross-sectional waves (2007--2008, 2009--2010, and 2011--2012), providing an initial total sample of 30,442 participants (11,823 children and 18,619 adults). Urinary phthalate concentrations were determined for 7765 subsets (2180 children and 5585 adults); therefore, only these participants were used for analysis. All selected participants provided informed consent in writing during the period of recruitment (NHANES [@CR42]).

Measurement of phthalate metabolites {#Sec4}
------------------------------------

Phthalate metabolites were measured in a spot urine sample of a randomly selected one third sub-sample of the study respondents. These collected samples were frozen at the temperature of − 20 °C and shipped to the division of Environmental Health Laboratory Sciences, National Centre for Environmental Health, CDC for the analysis of various phthalate metabolites. In order to reduce the possibility of exposure misclassification (James-Todd et al. [@CR28]), phthalate metabolites were measured instead of their parent compound. A full description of the analytical methods employed for the measurement of phthalates metabolites have been described elsewhere (Laboratory Procedure Manual [@CR36]).

A combination of phthalate metabolites that have been previously studied and those that were measured in all the three cross-sectional waves, with more than 60% of the sample concentrations at or above the limit of detection (LOD) (James-Todd et al. [@CR28]) were selected for this project. These included ten (10) phthalate metabolites: mono-(carboxynonyl) phthalate (MCNP), mono-(2-ethyl-5-carboxypentyl) phthalate (MECPP), MEHP, mono-(2-ethyl-5-hydroxylhexyl) phthalate (MEHHP), mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP), mono-n-butyl phthalate (MnBP), mono-iso-butyl phthalate (MiBP), MBzP, MEP and mono-(3-carboxylpropyl) phthalate (MCPP).

Given that the LOD for phthalate metabolites differed across each survey cycle, the maximum limit of detection (LOD~max~) was used to standardise each phthalate detection limits in the three cross-sectional waves (Varshavsky et al. [@CR51]). Thus, all concentrations below the LOD~max~ were substituted with the value of LOD~max~ divided by the square root of two (Varshavsky et al. [@CR51]).

Asthma data {#Sec5}
-----------

### Self-reported questionnaire data {#Sec6}

NHANES collected information on asthma and associated symptoms using a self-administered questionnaire completed at the NHANES clinic visit. Following the recommendation from the European birth cohort study (Carlsen et al. [@CR15]), current asthma was defined by respondents giving a positive response to both questions: "Has a doctor or other health professional ever told you that you have asthma?" and "In the past 12 months (have you/has SP) had wheezing or whistling in (your/his/her) chest?"

### Spirometry data {#Sec7}

Spirometry data were available in all cross-sectional waves and were also used for asthma determination. Participants aged 6 to 79 years were considered eligible for spirometry testing. Respondents were excluded if they: had current chest pain or physical problems with forceful expiration; had recent chest, eye or abdominal surgery; had a heart problem (such as heart attack), stroke or tuberculosis; were taking supplementary oxygen; had a collapsed lung or detached retina; had painful ear problems or had coughed up blood recently (NHANES [@CR40]).

Spirometry testing for eligible participants was performed following the procedures recommended by the American Thoracic Society (ATS). The protocol and procedures for spirometry testing have been described elsewhere (NHANES [@CR41]). The baseline spirometry results of forced expiratory volume in 1 s (FEV~1~), forced vital capacity (FVC) and FEV~1~/FVC% were determined by adopting a normal equation for spirometry parameters of the US population which takes into account each respondent's age, sex, weight, height and race/ethnicity (NHANES [@CR40]).

Based on the guidelines set from the International Consensus Statement between the ATS and the European Respiratory Society (ERS) which suggest the presence of airflow obstruction when the FEV1/FVC ratio was less than 70% (Cerveri et al. [@CR18]), current untreated asthma was defined via spirometry results as respondents with an FEV1/FVC of \< 70% (Abo-Zaid et al. [@CR1]). Analyses using self-reported but not with spirometry data were performed for children. This is because accuracy and precision suffer in spirometry testing involving children (Murray et al. [@CR39]).

### Confounding variables {#Sec8}

Information on covariates was obtained from the NHANES. These covariates were determined using the self-reported questionnaire, physical examination, and laboratory measurements. Age, sex, race/ethnicity and poverty status (which serves as a proxy for socioeconomic status (SES)) were ascertained via questionnaire. Poverty status was defined by the poverty income ratio (PIR) which was calculated by dividing the family income by the poverty guidelines of a specific survey year. Race/ethnicity was classified as "non-Hispanic white" (referent group), "non-Hispanic black", "Mexican-American," and "Other".

Waist circumference in centimetres (cm) was used as a measure of overweight since it gives a better measure of obesity-related health risks than body mass index (BMI) (Janssen et al. [@CR29]). Urinary creatinine concentrations were measured using Roche/Hitachi Modular P chemistry analyser and Synchron CX3 clinical analyser (Beckman, CA, USA). Serum cotinine level (a biomarker for smoking status) was categorised as \< LOD (\< 0.015) nanogram/ml (ng/ml) (referent), low levels (≥ 0.015--10 ng/ml) and high levels (≥ 10 ng/ml).

### Statistical analysis {#Sec9}

The Spearman's rank correlation coefficient was used to examine phthalate metabolite correlation. Phthalate metabolite was considered to have a strong correlation with a Spearman's correlation coefficient (*r*~*s*~) greater than or equal to 0.7 (*r*~*s*~ ≥ 0.7). MEHP (a primary metabolite) and MECPP, MEHHP and MEOHP (secondary metabolites) of DEHP were strongly correlated with one another (with a value of *r*~*s*~ between 0.73--0.98) ([Additional file 1](#Sec13){ref-type="sec"}: Table [S1](#MOESM1){ref-type="media"}). Therefore, these metabolites were not separately analysed given their strong correlation and common source; the molar sum of DEHP denoted as "ΣDEHP", was used instead (Hoppin et al. [@CR24]).

Sampling weights, stratification and clustering provided in the NHANES study were applied to all statistical analysis in order to account for the complex, multistage sampling design employed in the selection of the representative non-institutionalised US population as well as obtaining accurate estimates that will not overstate the statistical significance. Following the NHANES analytical guidelines (Johnson et al. [@CR31]), a new sampling weight for the combined survey cycle was constructed by dividing the 2-year weights for each cycle by 3 which was applied to the data via the Stata command \[svyset\] prior to analysis.

Descriptive statistics (weighted means, standard deviation, weighted percentages and 95% confidence interval (CI)) were used to describe the demographics of all children and adults and their respective subsets with measured urinary phthalate metabolite concentrations. The distribution of urinary phthalate metabolites were presented for both children and adults using weighted geometric means, 95% CI and percentiles.

Logistic regression models (models 1 and 2) were used to determine the cross-sectional measure of the association between urinary phthalate metabolites (continuous) and current asthma (dichotomous outcome) by estimating the odds ratios (ORs) and 95% CIs per one log~10~ unit change in the concentration of phthalate metabolites. Model 1 was presented as unadjusted ORs and 95% CI. Model 2 was adjusted for urinary creatinine (log~10~ transformed, continuous) in addition to other potential confounding variables.

Potential confounders included in this analysis were those suggested as being linked with phthalate metabolites and/or asthma (Hoppin et al. [@CR24]; James-Todd et al. [@CR28]; Gascon et al. [@CR22]; Buckley et al. [@CR13]). These variables included age, sex, race/ethnicity, waist circumference, PIR, cotinine and urinary creatinine. The analysis was further stratified by sex for both children and adults by applying similar statistical modeling.

In order to assess the robustness of our findings, a sensitivity analysis was performed. Exposure-response relationships were examined by modeling the associations between tertiles of phthalate creatinine-corrected concentrations and asthma, with the lowest tertile considered as the reference category (Buckley et al. [@CR13]). Tertiles were categorised separately for children and adults such that each tertile contained an equal number of participants. While results for each phthalate metabolite were presented as crude and adjusted ORs and 95% CIs, only adjusted models were shown for effect modifications by sex and sensitivity analyses. All statistical analyses were conducted using STATA version 15.0 (College Station, TX, USA).

Results {#Sec10}
=======

The demographic characteristics of all children (*n* = 11,823) and the subset with measured urinary phthalate concentrations (*n* = 2180), who participated in the NHANES 2007--2012 are shown in Table [2](#Tab2){ref-type="table"}. Approximately 8% of children in both groups had self-reported asthma. With spirometry measures, the proportion of respondents with current asthma dropped to less than 2%. The weighted proportions of all children belonging to any race or living below the poverty threshold \[poverty-to-income ratio (PIR)\] were somewhat similar to those with measured phthalate metabolites.Table 2Demographic and asthma status for all children and subsets sampled for phthalate concentrations, NHANES 2007--2012Children aged 6 to \< 18 yearsCharacteristicsAll participants (*n* = 11823)Participants sampled for phthalate concentrations (*n* = 2180)Age at screening (years), weighted mean (SD, 95% CI)8.6 (5.2, 8.44--8.74)11.5 (3.4, 11.27--11.71)Sex  Male, weighted % (*n*, 95% CI)50.8 (6037, 49.26--52.25)50.1 (1095, 47.09--53.00)  Female, weighted % (*n*, 95% CI)49.2 (5786, 47.75--50.74)49.9 (1085, 46.99--52.91)Race/ethnicity, weighted % (*n*, 95% CI)  Non-Hispanic whites55.5 (3646, 50.57--60.39)56.1 (619, 50.38--61.62)  Non-Hispanic Blacks14.3 (2801, 11.99--17.04)14.7 (551, 12.13--17.73)  Mexican American Hispanic15.0 (2983, 12.04--18.63)14.8 (537, 11.48--18.77)  Others15.1 (2575, 12.90--17.58)14.4 (473, 11.74--17.66)  Waist circumference (cm), weighted mean (SD, 95% CI)67.8 (16.2, 67.25--68.34)73.1 (15.4, 72.10--73.99)Family income-to-poverty ratio (PIR), weighted % (n, 95% CI)  Below poverty (PIR \< 1), weighted % (*n*, 95% CI)24.4 (3823, 21.97--27.03)23.7 (668, 20.85--26.82)  At or above poverty (PIR ≥ 1),75.6 (7052, 72.97--78.03)76.3 (1333, 73.18--79.15)  Urinary creatinine (mg/dL), weighted mean (SD, 95% CI)119.2 (74.2, 114.76--123.69)118.6 (75.3, 113.76--123.36)Cotinine levels (ng/mL), weighted % (*n*, 95% CI)  \< LOD (\< 0.015)25.9 (1554, 23.03--29.13)26.8 (457, 22.94--30.99)  Low (≥ 0.015 to \< 10)70.4 (4855, 67.15--73.42)68.7 (1322, 64.72--72.47)  High (≥ 10)3.7 (184, 2.96--4.50)4.5 (63, 3.18--6.33)Current asthma based on self-reported questionnaire, weighted % (*n*, 95% CI)  Yes7.6 (800, 7.13--8.14)8.1 (177, 6.80--9.71)  No92.4 (9700, 91.86--92.87)91.9 (2003, 90.29--93.20)Current asthma based on spirometry FEV~1~/FVC cutoff, weighted % (*n*, 95% CI)  Yes1.7 (110, 1.28--2.12)1.5 (34, 1.02--2.07)  No98.3 (5737, 97.88--98.72)98.6 (1877, 97.93--98.98)*SD* standard deviation, *CI* confidence interval, *LOD* limit of detection, *FEV1* forced expiratory volume in 1 s, *FVC* forced vital capacity

Of the 30,442 respondents in the NHANES 2007--2012 cross-sections, a total of 61.2% (*n* = 18,619) were adults - with approximately a third (*n* = 5585) of the participants sub-sampled for phthalate metabolite levels (Table [3](#Tab3){ref-type="table"}). Although adults with detectable phthalate metabolite values were slightly younger when compared with all adults, there was no difference in the weighted proportions of the subjects belonging to any race or living below the poverty threshold \[poverty-to-income ratio (PIR) \< 1).Table 3Demographic and asthma status for all adults and subsets sampled for phthalate concentrations, NHANES 2007--2012Adults aged 18 to \< 80 yearsCharacteristicsAll participants (*n* = 18619)Participants sampled for phthalate concentrations (n = 5585)Age at screening (years), weighted mean (SD, 95% CI)46.1 (17.3, 45.33--46.82)44.2 (16.1, 43.36--45.00)Sex  Male, weighted % (*n*, 95% CI)48.3 (9140, 47.59--49.06)49.4 (2804, 47.95--50.94)  Female, weighted % (*n*, 95% CI)51.7 (9479, 50.94--52.41)50.6 (2781, 43.37--52.05)Race/ethnicity, weighted % (*n*, 95% CI)  Non-Hispanic whites67.6 (8044, 63.20--71.62)67.1 (2323, 62.74--71.25)  Non-Hispanic Blacks11.6 (4050, 9.60--13.84)11.9 (1271, 9.80--14.33)  Mexican American Hispanic8.4 (2913, 6.48--10.75)8.3 (893, 6.36--10.78)  Others12.5 (3612, 10.70--14.61)12.7 (1098, 10.81--14.81)  Waist circumference (cm), weighted mean (SD, 95% CI)97.9 (16.2, 97.27--98.43)97.8 (16.7, 97.05--98.60)Family income-to-poverty ratio (PIR), weighted % (*n*, 95% CI)  Below poverty (PIR \< 1),16.1 (4003, 14.56--17.78)16.2 (1233, 14.20--18.50)  At or above poverty (PIR ≥ 1),83.9 (12834, 82.15--85.44)83.8 (3837, 81.50--85.80)  Urinary creatinine (mg/dL), weighted mean (SD, 95% CI)120.8 (77.9, 117.84--123.81)121.4 (78.7, 118.28--124.49)Cotinine levels (ng/mL), weighted % (*n*, 95% CI)  \< LOD (\< 0.015)24.9 (3724, 23.28--26.69)25.1 (1130, 22.90--27.35)  Low (≥ 0.015 to \< 10)50.0 (8844, 48.47--51.50)49.2 (2705, 46.83--51.49)  High (≥ 10)25.1 (4216, 23.58--26.60)25.8 (1379, 23.60--28.10)Current asthma based on self-reported questionnaire, weighted % (*n*, 95% CI)  Yes5.9 (1123, 5.29--6.75)5.7 (349, 4.93--6.47)  No94.0 (17,463, 93.24--94.71)94.3 (5227, 93.53--95.07)Current asthma based on spirometry FEV~1~/FVC cut-off, weighted % (n, 95% CI)  Yes13.4 (1818, 12.42--14.52)13.6 (610, 12.19--15.05)  No86.6 (12,353, 85.48--87.58)86.4 (4966, 84.95--87.81)*SD* standard deviation, *CI* confidence interval, *LOD* limit of detection, *n* number of observation, *FEV*~*1*~ forced expiratory volume in 1 s, *FVC* forced vital capacity

Self-reported asthma was seen in nearly 6% of both groups. With the spirometry measure, the proportion of asthmatics was more than doubled. This is expected given the nature of the US healthcare system with many adults in the US without health insurance and thus with undiagnosed asthma (Baldacci et al. [@CR6]).

All participants (children and adults) had detectable concentrations of both LMW and HMW phthalate metabolites (detection frequency \> 60%) (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). With regard to LMW phthalates, MEP had the highest mean concentrations for both children and adults. For HMW phthalates, MECPP showed the highest in both groups.Table 4Distribution of urinary phthalate concentrations for children (aged 6 to \< 18 years), NHANES 2007--2012PercentileMetabolite (ng/mL)Sample size, *N*LOD~max~ (ng/mL)≥ LOD~max~ (%)^a^Weighted geometric mean (95% CI)Min5th25th50th75th95thMaxLMW phthalate  MEP21060.699.945.2 (39.85--50.45)\< LOD~max~6.922.849.5129.1588.97633.2  MiBP21060.399.69.7 (9.05--10.37)\< LOD~max~1.55.411.522.256.21163.3  MnBP21060.698.418.2 (16.56--19.89)\< LOD~max~2.310.422.244.4118.3101013HMW phthalate  MBzP21060.399.410.6 (9.55--11.67)\< LOD~max~1.25.012.327.386.1617.18  MCNP21060.596.33.0 (2.72--3.19)\< LOD~max~0.51.73.15.514.6334  MCPP21060.298.54.0 (3.56--4.39)\< LOD~max~0.61.93.88.024.91425.8  ΣDEHP^b^2106----0.2 (0.17--0.21)0.0040.030.100.200.401.4315.57  MEHP21061.166.72.1 (1.96--2.23)\< LOD~max~\< LOD~max~\< LOD~max~1.94.215.3204.7  MEHHP21060.799.416.1 (14.58--17.65)\< LOD~max~2.27.817.236.5133.31672  MECPP21060.510027.1 (24.67--29.56)\< LOD~max~5.014.628.456.4194.11871  MEOHP21060.699.110.2 (9.30--11.17)\< LOD~max~1.55.111.222.876.81175.1Table 5Distribution of urinary phthalate concentrations for adults (aged 18 to \< 80 years), NHANES 2007--2012PercentileMetabolite (ng/mL)Sample size, *N*LOD~max~ (ng/mL)≥ LOD~max~ (%)^a^Weighted geometric mean (95% CI)Min5th25th50th75th95thMaxLMW phthalate  MEP54170.699.963.6 (58.95--68.35)\< LOD~max~6.826.172.1224.3128531,660  MiBP54170.398.76.5 (6.12--6.90)\< LOD~max~0.93.88.115.540.0627  MnBP54170.697.211.9 (10.96--12.79)\< LOD~max~1.36.815.030.884.825,863HMW phthalate  MBzP54170.397.85.3 (4.93--5.63)\< LOD~max~0.62.55.913.442.3450.2  MCNP54170.592.72.6 (2.42--2.72)\< LOD~max~\< LOD1.22.44.816.2730.25  MCPP54170.297.42.8 (2.54--2.99)\< LOD~max~0.31.22.65.622.42597.3  ΣDEHP^b^5417----0.1 (0.13--0.15)0.0030.020.070.140.301.1106.72  MEHP54171.162.82.1 (1.92--2.20)\< LOD~max~\< LOD~max~\< LOD~max~1.74.016.91252.7  MEHHP54170.798.512.5 (11.52--13.52)\< LOD~max~1.65.912.827.3116.39326.1  MECPP54170.599.819.5 (17.99--20.92)\< LOD~max~3.19.519.840.7148.115828  MEOHP54170.697.87.5 (6.90--8.07)\< LOD~max~1.03.67.716.162.16079.9*N* number of participants/urinary samples, *LOD* limit of detection, *Min* minimum, *5th* 5th percentile, *25th* 25th percentile, *50th* 50th percentile, *75th* 75th percentile, *95th* 95th percentile, *Max* maximum, *LMW* low molecular weight, *MMP* mono-n-methyl phthalate, *MEP* mono-ethyl phthalate, *MiBP* mono-isobutyl phthalate, *MnBP* mono-n-butyl phthalate, *HWM* high molecular weight, *MiNP* mono-isononyl phthalate, *MBzP* mono-benzyl phthalate, *MCNP* mono (carboxylnonyl) phthalate, *MCPP* mono-(3-carboxylpropyl) phthalate, *DEHP* di(2-ethylhexyl) phthalate, *MEHP* mono-(2-ethylhexyl) phthalate, *MEHHP* mono-(2-ethyl-5-hydroxylhexyl) phthalate, *MECPP* mono-(2-ethyl-5-carboxylpentyl) phthalate, *MEOHP* mono-(2-ethyl-5-oxohexyl) phthalate^a^Percentage of phthalate metabolite concentrations at or above the maximum limit of detection (\< LOD~max~). All concentrations below the LOD~max~ (\< LOD~max~) were substituted with a value of LOD~max~ divided by square root of two (√2)^b^ΣDEHP: molar sum of DEHP metabolites (MEHP, MEHHP, MECPP and MEOHP) expressed in μmol/L.

The crude and adjusted model of associations between the different phthalate metabolites and self-reported asthma in children are shown in Fig. [1](#Fig1){ref-type="fig"} a and b, respectively. Self-reported childhood asthma was positively associated with MEP (1.45; 1.10--1.92), MiBP (1.62; 1.12--2.32), MnBP (1.46; 1.05--2.02) and MBzP (1.50; 1.09--2.08) in the crude analysis; with only MBzP (1.54; 1.05--2.27) reaching statistical significance after adjusting for confounding variables.Fig. 1**a** Model 1 (crude) - associations of urinary phthalate metabolites with self-reported asthma in children, NHANES 2007--2012. Logistic regression modeling was used to access the effect of individual phthalate metabolites on asthma prevalence, with an odds ratio (OR) presented for 1 log~10~ unit change in urinary phthalate concentration. **b** Model 2 (adjusted)---associations of urinary phthalate metabolites with self-reported asthma in children, NHANES 2007--2012. Logistic regression modeling was used to access the effect of individual phthalate metabolites on asthma prevalence, with an OR presented for 1 log~10~ unit change in urinary phthalate concentration. MEP mono-ethyl phthalate, MiBP mono-isobutyl phthalate, MnBP mono-n-butyl phthalate, MBzP mono-benzyl phthalate, MCNP mono-(carboxynonyl) phthalate, MCPP mono-(3-carboxylpropyl) phthalate, ΣDEHP molar sum of DEHP metabolites (MEHP, MEHHP, MECPP and MEOHP). All models were adjusted for age, sex, ethnicity/race, waist circumference, cotinine, poverty and urinary creatinine

Stratification by child's sex revealed that only the association between MEP and current asthma was modified, with a significant positive relationship among boys (2.00; 1.14--3.51), but not among girls (Fig. [2](#Fig2){ref-type="fig"}). Effect modification was not observed for MBzP, despite the significant relationship found in the overall model.Fig. 2Associations between urinary phthalate metabolites and asthma (self-reported) in children stratified by sex. Logistic regression modeling was used to access the effect of individual phthalate metabolites on asthma prevalence, with odds ratio (OR) presented for 1 log~10~ unit change in urinary phthalate concentration. MEP mono-ethyl phthalate, MiBP mono-isobutyl phthalate, MnBP mono-n-butyl phthalate, MBzP mono-benzyl phthalate, MCNP mono-(carboxynonyl) phthalate, MCPP mono-(3-carboxylpropyl) phthalate, ΣDEHP molar sum of DEHP metabolites (MEHP, MEHHP, MECPP and MEOHP). All models were adjusted for age, race/ethnicity, waist circumference, poverty, urinary creatinine and cotinine

The crude and adjusted analyses of associations between different phthalate metabolites and self-reported asthma in adults are shown in Fig. [3](#Fig3){ref-type="fig"} a and b, respectively. No phthalate metabolite showed a clear significant association with self-reported asthma in either the crude or the adjusted models. Effect modification by adult sex was not observed between any phthalate metabolites and self-reported asthma (Fig. [4](#Fig4){ref-type="fig"}).Fig. 3**a** Model 1 (crude)---associations of urinary phthalate metabolites with self-reported asthma in adults, NHANES 2007--2012. Logistic regression modeling was used to access the effect of individual phthalate metabolites on asthma prevalence, with odds ratio (OR) presented for 1 log~10~ unit change in urinary phthalate concentration. **b** Model 2 (adjusted) - associations of urinary phthalate metabolites with self-reported asthma in children, NHANES 2007--2012. Logistic regression modeling was used to access the effect of individual phthalate metabolites on asthma prevalence, with odds ratio (OR) presented for 1 log~10~ unit change in urinary phthalate concentration. MEP mono-ethyl phthalate, MiBP mono-isobutyl phthalate, MnBP mono-n-butyl phthalate, MBzP mono-benzyl phthalate, MCNP mono-(carboxynonyl) phthalate, MCPP mono-(3-carboxylpropyl) phthalate, ΣDEHP molar sum of DEHP metabolites (MEHP, MEHHP, MECPP and MEOHP). All models were adjusted for age, sex, ethnicity/race, waist circumference, cotinine, poverty and urinary creatinineFig. 4Associations between urinary phthalate metabolites and asthma (self-reported) in adults stratified by sex. Logistic regression modeling was used to access the effect of individual phthalate metabolites on asthma prevalence, with odds ratio (OR) presented for 1 log~10~ unit change in urinary phthalate concentration. MEP mono-ethyl phthalate, MiBP mono-isobutyl phthalate, MnBP mono-n-butyl phthalate, MBzP mono-benzyl phthalate, MCNP mono-(carboxynonyl) phthalate, MCPP mono-(3-carboxylpropyl) phthalate, ΣDEHP molar sum of DEHP metabolites (MEHP, MEHHP, MECPP and MEOHP). All models were adjusted for age, race/ethnicity, waist circumference, urinary creatinine and cotinine

Association of urinary phthalate metabolites, and current asthma in adults were re-analysed using spirometry data, with the results presented in Fig. [5](#Fig5){ref-type="fig"} a and b. MiBP was inversely associated with asthma in adults in the unadjusted model (0.73; 0.59--0.89), but the association did not reach statistical significance after adjusting for confounders. No other phthalate metabolites showed a significant relationship in either the crude nor the adjusted analyses.Fig. 5**a** Model 1 (crude)---associations of urinary phthalate metabolites with current asthma (spirometry measure) in adults, NHANES 2007--2012. Logistic regression modeling was used to access the effect of individual phthalate metabolites on asthma prevalence, with odds ratio (OR) presented for 1 log~10~ unit change in urinary phthalate concentration. **b** Model 2 (adjusted)---associations of urinary phthalate metabolites with current asthma (spirometry measure) in adults, NHANES 2007--2012. Logistic regression modeling was used to access the effect of individual phthalate metabolites on asthma prevalence, with odds ratio (OR) presented for 1 log~10~ unit change in urinary phthalate concentration. MEP mono-ethyl phthalate, MiBP mono-isobutyl phthalate, MnBP mono-n-butyl phthalate, MBzP mono-benzyl phthalate, MCNP mono-(carboxynonyl) phthalate, MCPP mono-(3-carboxylpropyl) phthalate, ΣDEHP molar sum of DEHP metabolites (MEHP, MEHHP, MECPP and MEOHP). All models were adjusted for age, sex, ethnicity/race, waist circumference, cotinine, poverty, and urinary creatinine

The association of current asthma with MEP, MCPP and MCNP were not apparent in the overall model until after stratification by sex (Fig. [6](#Fig6){ref-type="fig"}). Similar to the result observed in children, a positive significant relationship was found between MEP and current asthma among adult males (1.32; 1.04--1.69) but not for females (1.03; 0.75--1.44). In contrast, MCPP and MCNP were negatively associated with current asthma in adult females alone.Fig. 6Associations between urinary phthalate metabolites and current asthma (spirometry measure in adults stratified by sex. Logistic regression modeling was used to access the effect of individual phthalate metabolites on asthma prevalence, with odds ratio (OR) presented for 1 log~10~ unit change in urinary phthalate concentration. MEP mono-ethyl phthalate, MiBP mono-isobutyl phthalate, MnBP mono-n-butyl phthalate, MBzP mono-benzyl phthalate, MCNP mono-(carboxynonyl) phthalate, MCPP mono-(3-carboxylpropyl) phthalate, ΣDEHP molar sum of DEHP metabolites (MEHP, MEHHP, MECPP and MEOHP). All models were adjusted for age, race/ethnicity, waist circumference, urinary creatinine and cotinine

Sensitivity analyses examining the exposure-response associations demonstrated increases or decreases in the odds of current asthma with increasing exposure category ([Additional file 1](#Sec13){ref-type="sec"}: Tables [S2](#MOESM1){ref-type="media"}, [S3](#MOESM1){ref-type="media"} and [S4](#MOESM1){ref-type="media"}). Overall, the results were consistent with the primary analysis in both children and adults. There was a significant positive association between MBzP exposure and self-reported asthma in children for the highest tertile relative to the lowest tertile (1.99; 1.08--3.68), but not with any other phthalate metabolites. For male children, exposure to the highest tertile of MEP was significantly associated with over a 2-fold increased odds of self-reported asthma compared to the lowest tertile of MEP (2.38; 1.107--5.29). Similarly, adult males in the middle (1.64; 1.01--2.68) and highest tertiles (1.66; 1.07--2.2.59) had an elevated odds of asthma compared to those in the lowest tertiles. With the exception of MEP, no other phthalate metabolites showed a positive association with current asthma in males.

Results were, however, less consistent for adult females, with no significant relationship found using spirometry data as opposed to the inverse association found between MCNP and MCPP metabolites and current asthma in the primary analysis.

Discussion {#Sec11}
==========

In this study, we observed no clear relationship between phthalate exposure and asthma, apart from one significant association between MBzP and self-reported asthma in children. Stratification by sex revealed that both boys and adult males are not at increased odds of current asthma following exposure to the majority of phthalate metabolites apart from the MEP metabolite. We found associations of MCNP and MCPP concentrations with reduced odds of asthma (defined using FEV~1~/FVC 70% cut off) among adult females. MiBP, MnBP and ΣDEHP were not significantly associated with either self-reported or objectively defined asthma (spirometry measure) in both children and adults.

Whyatt et al. ([@CR55]) examined the relationship between the diagnosis of asthma in children (aged 5--11 years, *n* = 300) and prenatal exposures BBzP, di-n-butyl phthalate (DnBP), DEHP and di-ethyl phthalate (DEP) using a longitudinal birth cohort of 727 women enrolled between 1998 and 2006. They found that maternal prenatal MBzP and MnBP concentrations---metabolites of HMW BBzP and DnBP, respectively---were significantly associated with the diagnosis of current asthma and with a history of asthma-like symptoms (Whyatt et al. [@CR55]). The present study found a significant association between MBzP and self-reported asthma in children, but no relationship was found for MnBP.

A positive correlation was found between an HMW metabolite, DEHP exposure and asthma in settled dust (Gascon et al. [@CR22]), but not with MBzP (Bornehag et al. [@CR11]; Kolarik et al. [@CR33]). A cross-sectional study of 623 Norwegian children aged 10 years old reported a significant relationship with the highest quartiles of MCNP and mono-(carboxyloctyl) phthalate (MCOP) (Bertelsen et al. [@CR8]). However, we did not find a positive association of childhood asthma with DEHP or MCNP in either the crude or the adjusted analyses. This disparity may be attributed in part to the matrix examined, dust (Gascon et al. [@CR22]; Bornehag et al. [@CR11]; Kolarik et al. [@CR33]) versus urine (Bertelsen et al. [@CR8]). Another possible explanation might be the differences in specimen collection (i.e. the use of first-morning void (Bertelsen et al. [@CR8]) as opposed to spot urine in the present study), as these may affect the concentrations of phthalate metabolites measured.

MBzP is a primary metabolite of BBzP, an HMW phthalate used in the manufacturing of toys, PVC materials, child care articles and personal care products, and for pharmaceutical coatings (Benjamin et al. [@CR7]; Braun et al. [@CR12]). While exposure to some phthalate compounds, particularly among asthmatics, may be via pharmaceuticals, Hoppin et al. ([@CR24]) suggested that the presence of MBzP in urine is unlikely to be as a result of the use of asthma medication since BBzP is not approved for pharmaceutical coatings. Compared with non-asthmatics, Hsu et al. ([@CR26]) (Hsu et al. [@CR26]) demonstrated that asthmatic children had significantly higher levels of BBzP determined in settled dust, even after controlling for other indoor air pollutants. They proposed that the inhalation of BBzP may be an important pathway to the development or exacerbation of asthma in children in Taiwan (Hsu et al. [@CR26]).

In a study using the NHANES data, Hoppin et al. ([@CR24]) showed that HMW phthalate metabolites, particularly MBzP, were positively associated with current asthma, current wheeze, current hay fever, and current rhinitis in adults (aged 18 years and older, *n* = 1596), but not in children (aged 6--17 years, *n* = 779). This disparity with our analysis may be attributed to the asthma definition and/or the measurement method used. Hoppin et al. ([@CR24]) separated the definition of current asthma and wheeze in their analysis, whereas the present study combined these self-reported measures. It is also possible that our findings for children may have occurred by chance alone since no other phthalate analysed showed a significant relationship in the adjusted models.

We did observe that the weighted geometric mean concentration of MBzP in children was two-fold the level seen in adults (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). This suggests that children are more exposed to MBzP than adults and may be at increased odds of asthma following this exposure. It is important to note that our findings for children should, however, be interpreted with caution. While one (MBzP metabolite) out of ten metabolites analysed was positively associated with asthma, this does not suggest any strong relationship between phthalates and asthma. For adults, using both self-reported and spirometry data of the present study, there were no associations between any phthalate metabolite and current asthma.

With respect to effect modification by sex, Ku et al. ([@CR34]) reported that exposure to MEP metabolite was significantly associated with an increased odds of asthma among boys, but not among girls; and this was reflected in our study. Analysis of 240 adult participants (140 females, 100 males; 20 to 60 years) of NHANES III revealed that MEP levels in urine were associated with a reduction in pulmonary function measures (FEV1, FVC) in adult males alone (Hoppin et al. [@CR23]). A similar study of 3147 participants (aged between 6 and 49 years) found significant associations between MEP, MnBP, MCPP and ΣDEHP exposure, and a reduction in FEV~1~ or FVC in men (Cakmak et al. [@CR14]). Although an inverse association was found between MCPP and MCNP metabolites and current asthma in adult females, our result for MEP was consistent with previous studies for both boys and adult males.

MEP is a primary metabolite of DEP, an LMW phthalate used in varieties of consumer products including fragrances and personal care products. Sex differences in MEP concentrations have been explained based on the use of these products, with evidence of higher MEP levels in females than in males (Saravanabhavan et al. [@CR46]). However, our finding suggests that higher exposure to DEP may not explain the observed association among males. The sex-specific relationship may be attributed to either the endocrine disruptive ability of DEP in relation to sex differences in asthma prevalence (Buckley et al. [@CR13]), or the hormonal influence of the chemical on the functioning of lungs and the immune systems. It is also plausible that the interactions between gene and environmental exposure to DEP may have resulted in sex-specific differences and the observed male susceptibility to asthma prevalence.

Although the pathways through which phthalates induce asthma in humans remain unclear (Whyatt et al. [@CR55]), animal studies have provided stronger evidence of their deleterious effects. For example, the metabolites of HMW phthalates, especially MBzP and MEHP, were shown to bind with and activate the nuclear peroxisome proliferator-activated receptors (PPAR-alpha and PPAR-gamma), which play a significant role in certain physiological processes including airway remodeling and inflammation in rodents (Hurst and Waxman [@CR27]). More recently, in vivo studies have demonstrated that DEHP induces Th2 and Th17 immune responses and airway inflammation in mice (Alfardan et al. [@CR2]), and thymic stromal lymphopoietin (TSLP), Th2 immune response and interleukin-7 receptor in rats (Wang et al. [@CR54]); all of which exacerbates asthma.

Some limitations of the study include the cross-sectional design of NHANES making it difficult to establish causality in the associations between phthalate exposures and asthma in children and adults. Phthalate measurements are prone to exposure misclassification via the use of a single spot urine sample per subject, which may not take into account the variation of within-person over time. Nevertheless, although phthalate metabolites have biological half-lives of less than a day (Jepsen et al. [@CR30]; Ferguson et al. [@CR21]), research has shown that, despite this temporal variability, the measurement of phthalate concentrations via a single spot urine sample may be a representative of long-term exposures (Teitelbaum et al. [@CR49]). We were unable to repeat the analysis for children using spirometry data. This is because FEV~1~/FVC was considered a poor diagnostic test for childhood asthma due to a lack of accuracy and precision (Murray et al. [@CR39]) and the limited number of children classified as asthmatics (\< 2%) compared to non-asthmatics (\> 98%) (Table [2](#Tab2){ref-type="table"}). This prevented us from investigating if the observed association between MBzP metabolites and self-reported asthma in children were overestimated or due to chance. Finally, some children and adults with asthma, particularly of lower socio-economic status (SES), may not have received a diagnosis of asthma due to lack of healthcare; and thus, are unaware of their current asthma status.

However, the strengths of the study include using three NHANES waves based on a representative sample of the US population that is diverse in terms of geographical distribution, ethnic groups, age, and income. Current asthma was defined using both subjective (self-reported) and objective (spirometry) measures in adults. Both our primary and sensitivity analyses were robust in statistical modeling approaches and may be generalised to the US population.

Conclusions {#Sec12}
===========

Urinary concentrations of phthalate metabolites were not significantly associated with current asthma in children and adults, apart from a single metabolite. Stratification by sex revealed that boys and adult males were at increased odds of asthma following exposure to only MEP; adult females were at decreased odds of asthma following exposure to MCNP and MCPP. Based on our findings, the potential adverse effect of phthalate exposure on asthma pathogenesis and/or exacerbations remains controversial, highlighting the need for a more comprehensive study on phthalate exposure and the occurrence of asthma; ideally, integrating a well-designed longitudinal follow-up analysis would be more informative.
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